130
Participants
Start Date
February 21, 2022
Primary Completion Date
December 29, 2023
Study Completion Date
January 31, 2025
AB-205
Allogeneic genetically engineered human umbilical vein endothelial cells
Placebo
Placebo
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medical College/New York Presbyterian Hospital, New York
Fox Chase Cancer Center, Philadelphia
Medstar Georgetown University Hospital, Washington D.C.
University Of Maryland School Of Medicine, Baltimore
Emory University - Winship Cancer Institute, Atlanta
University of Miami - Sylvester Comprehensive Cancer Center, Miami
Sarah Cannon Research Institute, Nashville, Nashville
Vanderbilt-Ingram Cancer Center, Nashville
The Ohio State University Comprehensive Cancer Center, Columbus
Indiana University Simon Comprehensive Cancer Center, Indianapolis
University of Michigan, Ann Arbor
University of Iowa Hospitals & Clinics, Iowa City
University of Minnesota Medical Center, Fairview, Minneapolis
University of Illinois Cancer Center, Chicago
The University of Texas MD Anderson Cancer Center, Houston
Sarah Cannon Research Institute, Colorado, Denver
Banner MD Anderson Cancer Center, Gilbert
University of California, Los Angeles, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
UC San Diego Moores Cancer Center, San Diego
UC Davis Comprehensive Cancer Center, Sacramento
Oregon Health and Science University, Portland
Fred Hutchinson Cancer Center, Seattle
University of South Florida (USF) - H. Lee Moffitt Cancer Center and Research Institute, Tampa
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Hackensack University Medical Center, Hackensack
Lead Sponsor
California Institute for Regenerative Medicine (CIRM)
OTHER
Angiocrine Bioscience
INDUSTRY